InterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its Subsidiary
26 Avril 2023 - 1:19AM
InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba
Canndoc) ("
InterCure" or the
"
Company"), the leading medical
cannabis company outside of North America announces that on April
24, 2023, it was informed that a lawsuit was filed against the
Company in Tel Aviv-Jaffa District Court by minority shareholders
of its subsidiary, Cannolam. The lawsuit was filed as part of a
conflict between the shareholders and the Company, which is related
to disagreements concerning the ongoing management of Cannolam.
Intercure has conducted a preliminary review of
the claims made by the minority shareholders and believes that they
lack a valid legal basis. The Company is evaluating all legal
options, including potential counterclaims. The Company is
committed to vigorously defending its interests and will take all
legal actions available to it.
About InterCure
(dba
Canndoc)
InterCure (dba Canndoc) (NASDAQ: INCR) (TSX:
INCR.U) (TASE: INCR) is the leading, profitable, and fastest
growing cannabis company outside of North America. Canndoc, a
wholly owned subsidiary of InterCure, is Israel’s largest licensed
cannabis producer and one of the first to offer Good Manufacturing
Practices (GMP) certified and pharmaceutical-grade medical cannabis
products. InterCure leverages its market leading distribution
network, best in class international partnerships and a high-margin
vertically integrated "seed-to-sale" model to lead the fastest
growing cannabis global market outside of North America.
For more information, visit: http://www.intercure.co.
Forward-looking statement
This press release may contain forward-looking
statements. Forward-looking statements may include, but are not
limited to, statements relating to the outcomes of the noted
lawsuit. These statements are often characterized by terminology
such as “believes,” “hopes,” “may,” “anticipates,” “should,”
“intends,” “plans,” “will,” “expects,” “estimates,” “projects,”
“positioned,” “strategy” and similar expressions and are based on
assumptions and assessments made in light of management’s
experience and perception of historical trends, current conditions,
expected future developments and other factors believed to be
appropriate.. Forward-looking statements are not guarantees of
future performance and are subject to risks and uncertainties that
could cause actual results to differ materially from those
expressed or implied in such statements. Many factors could cause
InterCure’s actual activities or results to differ materially from
the activities and results anticipated in forward-looking
statements. Forward-looking information is based on a number of
assumptions and is subject to a number of risks and uncertainties,
many of which are beyond InterCure’s control, which could cause
actual results and events to differ materially from those that are
disclosed in or implied by such forward-looking information.
InterCure undertakes no obligation to update such forward-looking
information, whether as a result of new information, future events
or otherwise, except as expressly required by applicable law.
Contact:
InterCure Ltd.Amos Cohen, Chief Financial
Officeramos@intercure.co
Intercure (TSX:INCR.U)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Intercure (TSX:INCR.U)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025